Jilin University, School of Public Health, Epidemiology and Statistics, #1163, Xinmin Street, Changchun 130021, China.
Jilin University, School of Public Health, Epidemiology and Statistics, #1163, Xinmin Street, Changchun 130021, China.
Clin Chim Acta. 2018 Sep;484:207-212. doi: 10.1016/j.cca.2018.05.056. Epub 2018 Jun 1.
A growing number of researches manifest that DNA methylation has been considered as biomarker for the prognosis of bladder cancer (BC). However, the results are still in a discrepancy.
This meta-analysis was conducted in accordance with PRISMA guidelines. Studies evaluating the practicability of methylated DNA as a prognostic marker for BC were thoroughly searched via the PubMed, Web of science and the Cochrane Library databases from January 1st, 2000 to May 5th, 2018. The association between DNA methylation and overall survival (OS) and progression-free survival (PFS) was analyzed. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to assess the correlation between methylated DNA and prognostic value in BC by using multivariate survival analysis.
Nineteen studies were included. Patients with methylated DNA had poorer OS, compared with those with unmethylated DNA, the combined HR was 2.766 (95%CI: 2.099-3.806). Simultaneously, methylated DNA was considerably associated with shorter PFS (HR = 2.872, 95%CI: 1.971-4.185). Furthermore, DNA methylation had a significant association with gender (male vs female: OR = 1.486, 95% CI = 1.090-2.025), grade (3 vs 1-2: OR = 3.153, 95% CI = 2.006-4.955), tumor diameter (≤3 cm vs >3 cm: OR = 0.408, 95% CI = 0.277-0.602), number of tumors (single vs multiple: OR = 0.683, 95% CI = 0.501-0.932), stage (Ta vs T1: OR = 0.472, 95% CI = 0.342-0.654), (Ta-T1 vs T2-T4: OR = 0.338, 95% CI =0.210-0.543).
DNA methylation was negatively correlated with the prognosis of BC patients and might become a promising biomarker.
越来越多的研究表明，DNA 甲基化已被认为是膀胱癌（BC）预后的生物标志物。然而，结果仍存在差异。
本研究按照 PRISMA 指南进行。通过检索 PubMed、Web of Science 和 Cochrane Library 数据库，全面检索了 2000 年 1 月 1 日至 2018 年 5 月 5 日评估甲基化 DNA 作为 BC 预后标志物的实用性的研究。分析 DNA 甲基化与总生存期（OS）和无进展生存期（PFS）的相关性。采用多变量生存分析，用风险比（HRs）或比值比（ORs）及其 95%置信区间（95%CI）评估甲基化 DNA 与 BC 预后价值之间的相关性。
共纳入 19 项研究。与未甲基化 DNA 相比，甲基化 DNA 患者 OS 更差，合并 HR 为 2.766（95%CI：2.099-3.806）。同时，甲基化 DNA 与较短的 PFS 显著相关（HR=2.872，95%CI：1.971-4.185）。此外，DNA 甲基化与性别（男性与女性：OR=1.486，95%CI：1.090-2.025）、分级（3 级与 1-2 级：OR=3.153，95%CI：2.006-4.955）、肿瘤直径（≤3cm 与>3cm：OR=0.408，95%CI：0.277-0.602）、肿瘤数量（单发与多发：OR=0.683，95%CI：0.501-0.932）、分期（Ta 期与 T1 期：OR=0.472，95%CI：0.342-0.654）、（Ta-T1 期与 T2-T4 期：OR=0.338，95%CI=0.210-0.543）显著相关。
DNA 甲基化与 BC 患者的预后呈负相关，可能成为一种有前途的生物标志物。
